NEW YORK (GenomeWeb) – A year after obtaining approval for its OmniSeq Target tumor profiling panel from the New York State Department of Health, Roswell Park Cancer Institute (RPCI) has spun out a company, also called OmniSeq, to make the test and related assays available to other institutions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.

Simple de-identification methods can protect information in a database from attackers, a new study suggests.

In Science this week: approach to visualize chromatin structure in nuclei, and more.

Sep
07
Sponsored by
PerkinElmer

This webinar will address improvements in the library prep workflow for small RNA sequencing in serum and plasma.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.